Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)-Reference-Cited by-同舟云学术

Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November–2 December, 2017, Naples, Italy)

Published:2018-07-21 Issue:1 Volume:16 Page:
ISSN:1479-5876
Container-title:Journal of Translational Medicine
language:en
Short-container-title:J Transl Med

Author:

Ascierto Paolo A.,Puzanov Igor,Agarwala Sanjiv S.,Bifulco Carlo,Botti Gerardo,Caracò Corrado,Ciliberto Gennaro,Davies Michael A.,Dummer Reinhard,Ferrone Soldano,Gajewski Thomas F.,Garbe Claus,Luke Jason J.,Marincola Francesco M.,Masucci Giuseppe,Mehnert Janice M.,Mozzillo Nicola,Palmieri Giuseppe,Postow Michael A.,Schoenberger Stephen P.,Wang Ena,Thurin Magdalena

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12967-018-1568-6.pdf

Reference48 articles.

1. Lui P, Cashin R, Machado M, Hemels M, Corey-Lisle PK, Einarson TR. Treatments for metastatic melanoma: synthesis of evidence from randomized trials. Cancer Treat Rev. 2007;33:665–80.

2. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.

3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507–16.

4. Lu R, Turan T, Samayoa J, Marincola FM. Cancer immune resistance: can theories converge? Emerging Topics Life Sci. 2017;1:411–9.

5. Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, Wallden B, Marincola FM, Cesano A. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer. 2018;6(1):63.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Structural Basis of Selective Human Indoleamine‐2,3‐dioxygenase 1 (hIDO1) Inhibition;ChemMedChem;2021-07-29

2. Advances in anti-BRAF therapies for lung cancer;Investigational New Drugs;2021-01-21

3. Skin melanoma. State of the problem. Review;Russian Journal of Oncology;2020-08-18

4. Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion;Therapeutic Advances in Medical Oncology;2020-01

5. Status of Immune Oncology: Challenges and Opportunities;Biomarkers for Immunotherapy of Cancer;2019-09-10